Taub Institute: Genomics Core
AN NIA-FUNDED ALZHEIMER'S DISEASE RESEARCH CENTER

 

Columbia University
Irving Medical Center
Neurological Institute

710 West 168th Street, 3rd floor
(212) 305-1818


bottom bar
top
make an appointment

Clinical Trials

Clinical Trials Currently Recruiting (May 2024)



UPCOMING: Early Alzheimer’s Disease: PROGRESS- AD GSK4527226 [AL101] (GSK & Alector Inc.)
A Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101) a Sortilin IG1 Monoclonal Antibody in Patients with Early Alzheimer’s Disease.
Phase 2: IV Infusion every 4 weeks. Duration:72 week treatment. MCI due to AD up to mild AD. MMSE: 21-29, CDR:0.5 or 1. Age: 50-85 years. NCT06079190.
Procedures include: amyloid confirmation or amyloid PET, MRIs, Amyloid PET, Tau PET
(Dr. Honig) Call Katrina Causay 212-305-2077

UPCOMING: Mild Cognitive Impairment/Early Onset Alzheimer’s Disease: Focused UltraSound (NIA)
Non-invasive Blood-brain Barrier Opening in Alzheimer's Disease Patients Using Focused Ultrasound
Phase 1. Duration:5 visits. NCT04118764.
Amnestic Mild Cognitive Impairment/Alzheimer’s Disease. MMSE: 12-26. Age: ≥50.
Procedures include: MRI, Amyloid PET scan, Tau PET Scan, focused ultrasound treatment
(Dr. Honig/Dr. Konofagou) Call Sergio Jimenez-Gambin 212-342-1612

UPCOMING: Mild Cognitive Impairment/Early Onset Alzheimer's Disease (ALTITUDE-AD)
A Study to Evaluate Efficacy and Safety of Intravenous ACU193 in Participants with Early Alzheimer's Disease
ClinicalTrials.gov ID NCT06335173 Sponsor Acumen Pharmaceuticals.
Phase:2/3 IV infusion every 4 weeks. Duration: 80 weeks treatment. Followed by an optional 52-week open label extension.
MCI due to AD or mild AD. MMSE: ≥ 22 to 30, CDR score of 0.5 to 1. Age: 50-90
Procedures Include: Evidence of amyloid accumulation by either amyloid PET or CSF. MRIs, Amyloid PETs optional Tau PETs subset, optional LPs subset.
(Dr. Honig) Call Katrina Causay 212-305-2077

UPCOMING: Mild Cognitive Impairment/Early Onset Alzheimer's Disease (TargetTau-1)
A Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants with Early Alzheimer's Disease
ClinicalTrials.gov ID NCT06268886 Sponsor Bristol-Myers Squibb.
Phase 2: IV infusion every 4 weeks. Duration: 76 weeks treatment. Followed by an optional 96-week open label.
MCI due to AD or mild AD. MMSE: ≥ 22 to 30, CDR score of 0.5 to 1. Age: 50 Years to 80 Years.
Procedures include: Tau confirmation via plasma, Tau PETs, MRIs, optional Amyloid PETs, optional LPs
(Dr. Honig) Call Katrina Causay 212-305-2077

Early Age-Related Hearing Loss Investigation: EARHLI, (NIH/NIA)
A study to determine the effect of hearing intervention vs. health education comparator intervention on cognitive performance, social engagement, and brain organization/connectivity in adults with Amnestic MCI and Hearing Loss.
Phase 2: Hearing Aid vs. Health Education Comparator, Duration: 52 weeks.
Amnestic MCI, Mild to Moderate Hearing Loss. MMSE 2: >23, CDR: 0.5. Age: 55 - 75 years. NCT06174038.
Participants get free hearing aids by the study end.
Procedures include: Hearing test, MRI ( half the participants) blood test: pTau, APOE. (Dr. Justin Golub) Call Michael Gomez: 646-317-3252

Observational Studies Currently Recruiting (May 2024)


Mild Cognitive Impairment/Alzheimer’s Disease/ Normal Cognition: ADRC clinical core (NIH/NIA)
Alzheimer’s Disease Research Center Clinical Core
Duration: 2 hours visit (in person). Visits are every year for the duration of the study.
Mild Cognitive Impairment/Mild Alzheimer’s Disease/Normal Cognition. Age: 55-90.
Procedures include: MRI, LP.
(Dr. Noble) Call Naara Ramirez Estevez 212-305-9971

Healthy Volunteers with Cognitive Complaints: Diverse VCID (NINDS)
Diverse Vascular Contributions to Cognitive Impairment and Dementia
Duration: 3 years, yearly visit
Subjective memory complaints, stroke free, CDR 0 or 0.5; Age: 65-90; must co-enroll with ADRC
Procedures include: fasting blood draw, structural MRI, lifestyle questionnaires, list learning task
(Dr. Brickman) Call Christiane Hale 646-317-4072

Mild Alzheimer's Disease/Normal Cognition: AD Autoimmune (NIH/NINDS)
Autoimmune features in neurodegenerative disorders
Duration: 1 to 2 visits. 1.5hrs per visit. NCT04239079.
Mild Alzheimer's Disease/Amnestic Mild Cognitive Impairment/Normal Cognition. AD: MMSE: 20-26, CDR 0.5-1. Age: ≥55.
Procedures include: 100ml blood draw.
(Dr. Marder) Call Kim Tran 469-739-1748

Amnestic, visual, and language variants of Mild Cognitive Impairment/AD: ADVISe (NIH/NIA)
Longitudinal imaging of microglial activation in different clinical variants of Alzheimer's disease
Duration: 2 years, baseline visits and 2 year follow up. NCT04576793.
Amnestic Mild Cognitive Impairment/Amnestic Alzheimer's Disease/Posterior Cortical Atrophy/Logopenic Variant Primary
Progressive Aphasia/Normal Cognition. CDR 0, 0.5 or 1.0. Age: 50+.
Procedures include: MRI, Amyloid, Tau, and Inflammation PET scans, LP.
(Dr. Small/Noble) Call Anna Smith 212 305-1625

Mild Cognitive Impairment/Alzheimer's Disease: PAM (NIH/NIA)
Discovery and validation of genetic variants affecting microglial activation in Alzheimer's disease
Duration: 5 years, baseline MRI/PET scan and 4 year follow up for blood draw/cognitive testing.
aMCI/AD/Normal Cognition (with prior LP or amyloid PET scan). CDR 0, 0.5 or 1.0. Age: ≥ 50.
Procedures include: MRI, Inflammation PET scan. 
(Dr. Philip De Jager) Call Anna Smith 212 305-1625

Alzheimer’s Disease: DIAN (NIH/NIA)
Dominantly Inherited Alzheimer Network
Duration: Years. Every 1 to 3 years visits. NCT00869817.
Family members of a person with AD (proband) due to PSEN1, PSEN2, or APP mutations. MMSE: any. Age: ≥18; younger but no more than 10 years younger than proband’s AAO.
(Dr. Noble) Call Naara Ramirez Estevez 212-305-1894

Alzheimer’s Disease: EFIGA (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Caribbean Hispanics
Duration: 1.5 hours visit (in person). Visits are every 2 years for the duration of the study. Hispanic individuals or families with or without memory problems willing to participate. Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Angel Piriz 212-305-2309

Alzheimer’s Disease: AD Family Based Study (FBS) (NIH/NIA)
Late and Early Onset Alzheimer’s Disease
Duration: 1.5 hours visit (in person/over the phone). Every 2 years visit for the duration of the study. Any ethnic background families with AD family history and/or with multiple affected alive members willing to participate.
Age: Affected any age. Unaffected 50 or older.
(Dr. Mayeux) Call Pamela Del Rosario 212-304-7284, email: pd2727@cumc.columbia.edu.

Alzheimer’s Disease: DAWN (NIH/NIA)
Genetic Study of Alzheimer’s Disease in Hispanics and African Americans.
Duration: 1.5 hours visit (in person/over the phone).
Hispanic or African American individuals with and without memory problems.
Age: Affected and Unaffected 50 or older
(Dr. Reitz) Call Jenny Chavez 212-342-3029
(Dr. Tosto) Call Jennifer Cespedes 646-317-9317 email: dawnstudy_neuro@cumc.columbia.edu

Alzheimer’s in African American Families (NIH/NIA)
Recruiting African American families with at least one with cognitive impairment plus another family member willing to participate.
Duration: 1.5 hours visit (in person/over the phone).
Every 2 years visit for the duration of the study.
Age: Affected any age. Unaffected 50 or older.
(Dr. Reitz ) Call Jenny Chavez 212-342-3029

Alzheimer’s Disease: Asian Cohort Alzheimer’s Disease (ACAD) (NIH/NIA)
Late Onset Alzheimer’s Disease
Duration: 2 hours visit (in person/over the phone). Every 2 years visit for the duration of the study. Chinese, Korean or Vietnamese individuals with AD family history with or without memory problems willing to participate.
Age: Affected 60 and older.
(Dr. Mayeux) Call Fangcong (Nini) Cheng: 332-257-4055

Alzheimer’s Disease: Apathy (DoD and NIA)
Study of a molecular risk factor for Apathy in AD
Duration: 2 hours visit (in person). One single visit completes study participation.
Mild to moderate AD or probable AD (MMSE≥9 and ≤26)
Males and Females, ≥50 years.
Procedures include: Fasting blood draw (~13ml), study assessments.
(Dr. Clelland) Call Julia Anderson 646-774-6232

BH4 in Alzheimer’s Disease and Mild Cognitive Impairment (NIA)
Study of a Molecular Risk Factor for Cognitive Impairment in AD and MCI
Duration: 2 hours visit (in person). One single visit completes study participation. Mild to moderate or probable AD (MMSE ≥11 and ≤24, CDR=1.0); MCI (MMSE ≥24, CDR=0.5); Control (CDR=0)
Males and Females, ≥55 years.
Procedures include: Fasting blood draw (~40ml), and study assessments.
(Dr. Clelland) Call Julia Anderson 646-774-6232

Frontotemporal Dementia: ALLFTD (NIH/NIA/NINDS)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration Protocol
Duration: 3-6 hour visits, for 1-5 years. NCT04363684
National consortium enrolling: Behavioral Variant Frontotemporal Dementia/Non-Fluent Variant Primary Progressive Aphasia/Semantic Variant Primary Progressive Aphasia/ Frontotemporal Dementia-Amyotrophic Lateral Sclerosis.
Also enrolling asymptomatic members of families with mutation in MAPT, GRN, C9orf72, or strong family history of FTLD.
Age: ≥18, CDR 0, 0.5, 1, or 2.
Procedures include: MRI, optional LP, optional genetic testing.
(Dr. Honig) Call Andrea Farah 212 305-2371

Programs Currently Recruiting (May 2024)


Arts and Minds
The Studio Museum in Harlem, New York Historical Society, and El Museo del Barrio
Excluded: persons with depression (only), cognitively normal persons, and patients with dementia. Spanish-speakers are welcome.
Participants will explore the world of art and culture in these interactive 75-minute programs.
(Dr. Noble) Call Carolyn Halpin-Healy 646-755-3726

A Friend for Rachel
A companionship program
MCI, early AD, early PPA, FTD (if not too behavioral), early DLB (if no hallucinations). Must be mobile and able to go out without an aide.
Participants will spend a few hours a week with their student friend either exploring NYC or staying near home.
Call Jill Goldman 212-305-7382

bottom bar